FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $25.07, for a total transaction of $968,604.52. Following the transaction, the chief executive officer now directly owns 3,353,983 shares of the company’s stock, valued at approximately $84,084,353.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of FibroGen Inc (NASDAQ:FGEN) traded up 0.20% during trading on Monday, reaching $25.05. 206,732 shares of the company traded hands. The firm has a 50-day moving average price of $24.44 and a 200-day moving average price of $21.59. The firm’s market capitalization is $1.60 billion. FibroGen Inc has a 12 month low of $14.50 and a 12 month high of $27.30.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.01. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. Equities research analysts anticipate that FibroGen Inc will post ($2.05) EPS for the current year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Your IP Address:

Hedge funds and other institutional investors have recently made changes to their positions in the company. TLP Group LLC purchased a new position in shares of FibroGen during the third quarter valued at approximately $108,000. SG Americas Securities LLC purchased a new position in shares of FibroGen during the third quarter valued at approximately $246,000. Fox Run Management L.L.C. boosted its position in shares of FibroGen by 15.0% in the third quarter. Fox Run Management L.L.C. now owns 12,300 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,600 shares during the last quarter. Bayesian Capital Management LP purchased a new position in shares of FibroGen during the fourth quarter valued at approximately $321,000. Finally, Sei Investments Co. boosted its position in shares of FibroGen by 42.6% in the third quarter. Sei Investments Co. now owns 16,077 shares of the biopharmaceutical company’s stock valued at $333,000 after buying an additional 4,805 shares during the last quarter. Institutional investors own 47.74% of the company’s stock.

FGEN has been the subject of several research analyst reports. Royal Bank of Canada reaffirmed a “buy” rating on shares of FibroGen in a research report on Wednesday, January 18th. Stifel Nicolaus reaffirmed a “positive” rating and set a $33.00 price target on shares of FibroGen in a research report on Wednesday, January 18th. Finally, Zacks Investment Research lowered shares of FibroGen from a “buy” rating to a “hold” rating in a research report on Tuesday, December 13th. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $37.50.

About FibroGen

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.